Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Katie, Streicher"'
Autor:
Myron J. Levin, Andrew Ustianowski, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A. Near, Katie Streicher, Alexandre Kiazand, Mark T. Esser
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 6, Pp 1253-1268 (2024)
Abstract Introduction The phase 3 PROVENT and STORM CHASER studies evaluated AZD7442 (tixagevimab/cilgavimab) for pre-exposure and post-exposure prophylaxis of symptomatic coronavirus disease 2019 (COVID-19). We report the final 15-month results of b
Externí odkaz:
https://doaj.org/article/a0dc96dc6a4541d2935ee2e82a120a9f
Autor:
F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Douglas Arbetter, Seth Seegobin, Alexandre Kiazand, Katie Streicher, Nuria Martinez-Alier, Taylor S. Cohen, Mark T. Esser
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 3, Pp 521-533 (2024)
Abstract Introduction In the phase 3 TACKLE study, outpatient treatment with AZD7442 (tixagevimab/cilgavimab) was well tolerated and significantly reduced progression to severe disease or death through day 29 in adults with mild-to-moderate coronavir
Externí odkaz:
https://doaj.org/article/a14226d40c5149da9cdf80a70f127265
Autor:
Jeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, Claudia Chen, Scott Caveney, Anastasia A. Aksyuk, Katie Streicher, Sandhia Ponnarambil, Gene Colice
Publikováno v:
Pulmonary Therapy, Vol 10, Iss 1, Pp 53-67 (2023)
Abstract Introduction Annual influenza vaccinations are recommended for adolescents and adults with moderate to severe asthma. This study investigated the effect of tezepelumab, a human monoclonal antibody that blocks the activity of thymic stromal l
Externí odkaz:
https://doaj.org/article/48da0b76314b46618d9e94479e3ec038
Autor:
Gustavo H. Kijak, Bahar Ahani, Douglas Arbetter, Fernando Chuecos, Vancheswaran Gopalakrishnan, Jagadish Beloor, Tyler Brady, Amy Nguyen, Tiffany L. Roe, Nicolette Schuko, Tianhui Zhang, F. D. Richard Hobbs, Francisco Padilla, Elizabeth J. Kelly, Hugh Montgomery, Katie Streicher
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 12, Pp 2691-2707 (2023)
Abstract Introduction AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Viral evoluti
Externí odkaz:
https://doaj.org/article/81d8ce3337a543ba897387fe3803d1b4
Autor:
F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Kenneth Kim, Douglas Arbetter, Kelly W. Padilla, Venkatesh Pilla Reddy, Seth Seegobin, Katie Streicher, Alison Templeton, Rolando M. Viani, Eva Johnsson, Gavin C. K. W. Koh, Mark T. Esser
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 9, Pp 2269-2287 (2023)
Abstract Introduction We assessed effects of AZD7442 (tixagevimab/cilgavimab) on deaths from any cause or hospitalizations due to coronavirus disease 2019 (COVID-19) and symptom severity and longer-term safety in the TACKLE adult outpatient treatment
Externí odkaz:
https://doaj.org/article/b097c49509c946169ed5d2c270e2f249
Autor:
Lindsay E Clegg, Oleg Stepanov, Sam Matthews, Tom White, Seth Seegobin, Steven Thomas, Kevin M Tuffy, Mats Någård, Mark T Esser, Katie Streicher, Taylor S Cohen, Anastasia A Aksyuk
Publikováno v:
Clinical & Translational Immunology, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Objectives The evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) necessitates rapid methods for assessing monoclonal antibody (mAb) potency against emerging variants. Authentic virus neutralisation assays are cons
Externí odkaz:
https://doaj.org/article/d383527f067748c0a99eb961c96ff5ba
Autor:
Tyler Brady, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany L. Roe, Kuishu Ren, Kim Rosenthal, Patrick M. McTamney, Michael E. Abram, Katie Streicher, Elizabeth J. Kelly
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 5 (2022)
ABSTRACT AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of severe acut
Externí odkaz:
https://doaj.org/article/98d4176648a242c59e666ffdfbd7fce6
Autor:
Eric Tu, Kelly McGlinchey, Jixin Wang, Philip Martin, Steven L.K. Ching, Nicolas Floc’h, James Kurasawa, Jacqueline H. Starrett, Yelena Lazdun, Leslie Wetzel, Barrett Nuttall, Felicia S.L. Ng, Karen T. Coffman, Paul D. Smith, Katerina Politi, Zachary A. Cooper, Katie Streicher
Publikováno v:
JCI Insight, Vol 7, Iss 3 (2022)
Treatment with anti–PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non–small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment as
Externí odkaz:
https://doaj.org/article/c6a5fda9646e49b8adcbb817d655948e
Autor:
Pablo Forte-Soto, Muna Albayaty, Dennis Brooks, Rosalinda H Arends, John Tillinghast, Anastasia A Aksyuk, Jerome Bouquet, Cecil Chen, Asfiha Gebre, Robert J Kubiak, Venkatesh Pilla Reddy, Seth Seegobin, Katie Streicher, Alison Templeton, Mark T Esser
Publikováno v:
The Journal of Infectious Diseases. 227:1153-1163
Background AZD7442 is a combination of extended half-life, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)−specific neutralizing monoclonal antibodies (tixagevimab and cilgavimab). Methods This phase 1, first-in-human, randomized, doub
Autor:
Shu Wang, Jingya Wang, Varsha Kumar, Jodi L. Karnell, Brian Naiman, Phillip S. Gross, Saifur Rahman, Kamelia Zerrouki, Richard Hanna, Christopher Morehouse, Nicholas Holoweckyj, Hao Liu, Autoimmunity Molecular Medicine Team, Zerai Manna, Raphaela Goldbach-Mansky, Sarfaraz Hasni, Richard Siegel, Miguel Sanjuan, Katie Streicher, Michael P. Cancro, Roland Kolbeck, Rachel Ettinger
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Systemic lupus erythematosus (SLE) is associated with altered B cell responses but the underlying aetiology is still unclear. Here the authors show that a CD11chiT-bet+ B cell subset with a unique phenotype and transcriptome is increased in patients
Externí odkaz:
https://doaj.org/article/b12a066bb82147b99f7c7c8fcb7739ef